JP2016512259A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512259A5
JP2016512259A5 JP2016500760A JP2016500760A JP2016512259A5 JP 2016512259 A5 JP2016512259 A5 JP 2016512259A5 JP 2016500760 A JP2016500760 A JP 2016500760A JP 2016500760 A JP2016500760 A JP 2016500760A JP 2016512259 A5 JP2016512259 A5 JP 2016512259A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
difluoromethoxy
methoxypyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512259A (ja
JP6282721B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/021426 external-priority patent/WO2014158998A1/en
Publication of JP2016512259A publication Critical patent/JP2016512259A/ja
Publication of JP2016512259A5 publication Critical patent/JP2016512259A5/ja
Application granted granted Critical
Publication of JP6282721B2 publication Critical patent/JP6282721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500760A 2013-03-14 2014-03-06 Pde4阻害剤としての置換ピリジン及びピラジン化合物 Active JP6282721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786288P 2013-03-14 2013-03-14
US61/786,288 2013-03-14
PCT/US2014/021426 WO2014158998A1 (en) 2013-03-14 2014-03-06 Substituted pyridine and pyrazine compounds as pde4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009464A Division JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Publications (3)

Publication Number Publication Date
JP2016512259A JP2016512259A (ja) 2016-04-25
JP2016512259A5 true JP2016512259A5 (enExample) 2017-04-06
JP6282721B2 JP6282721B2 (ja) 2018-02-21

Family

ID=51530139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016500760A Active JP6282721B2 (ja) 2013-03-14 2014-03-06 Pde4阻害剤としての置換ピリジン及びピラジン化合物
JP2018009464A Active JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018009464A Active JP6505878B2 (ja) 2013-03-14 2018-01-24 Pde4阻害剤としての置換ピリジン及びピラジン化合物

Country Status (17)

Country Link
US (8) US20160009691A1 (enExample)
EP (2) EP2970212B1 (enExample)
JP (2) JP6282721B2 (enExample)
KR (1) KR102232221B1 (enExample)
CN (2) CN105143207B (enExample)
AU (2) AU2014241430B2 (enExample)
BR (1) BR112015022474B1 (enExample)
CA (1) CA2895209C (enExample)
DK (1) DK3345902T3 (enExample)
ES (1) ES2769181T3 (enExample)
IL (1) IL240804B (enExample)
MX (1) MX370188B (enExample)
NZ (1) NZ711587A (enExample)
RU (1) RU2668073C2 (enExample)
SG (2) SG11201504709PA (enExample)
TW (2) TWI623523B (enExample)
WO (1) WO2014158998A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143207B (zh) 2013-03-14 2018-04-24 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California Compounds for increasing neural plasticity
CA3135420A1 (en) * 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用
AU2020229779B9 (en) 2019-02-27 2025-09-18 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
US11104660B2 (en) 2019-04-23 2021-08-31 Tetra Discovery Partners, Inc. PDE4D inhibitors
WO2020227312A1 (en) * 2019-05-06 2020-11-12 Calcimedica, Inc. Synthesis of crac channel inhibitors
MX2022005399A (es) * 2019-11-07 2022-07-05 Small Pharma Ltd Compuestos.
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN111995585B (zh) * 2020-08-04 2022-01-25 常州大学 嘧啶乙酰胺类化合物及其作为磷酸二酯酶pde2活性抑制剂的应用
US11945796B2 (en) 2020-09-16 2024-04-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
TW202313009A (zh) 2021-07-28 2023-04-01 美商努拉生物科技公司 作為sarm1抑制劑之經取代的吡啶衍生物
CA3239565A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
CN116265440B (zh) * 2021-12-16 2024-09-27 贵州大学 一种水杨酮拼接吡啶酮类化合物及其制备方法及应用
EP4562001A1 (en) * 2022-07-27 2025-06-04 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN119698422A (zh) 2022-09-29 2025-03-25 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
CN116082254B (zh) * 2022-12-28 2025-04-11 浙江永太科技股份有限公司 一种1-烷基-1,2,4-三氮唑-3-甲醇的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP4321737B2 (ja) 1997-12-17 2009-08-26 塩野義製薬株式会社 新規ピリジン化合物
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
EP1355669B1 (en) 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
WO2004046113A2 (en) 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
GB0229281D0 (en) 2002-12-16 2003-01-22 Novartis Ag Organic compounds
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
KR101267392B1 (ko) * 2004-06-30 2013-05-23 주식회사 씨앤드씨신약연구소 피리딘 유도체 및 그의 제조방법
GB0425572D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd 1,7-Naphthyridines
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
NZ570847A (en) 2006-02-28 2011-10-28 Helicon Therapeutics Inc Therapeutic compounds
WO2007100852A1 (en) 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors
EP2060575A1 (de) 2006-04-19 2009-05-20 Boehringer Ingelheim International GmbH Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2007135026A2 (de) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituierte pteridine als therapeutika
JP2010505789A (ja) * 2006-10-04 2010-02-25 エフ.ホフマン−ラ ロシュ アーゲー Hdl−コレステロール上昇剤としての3−ピリジンカルボキサミド及び2−ピラジンカルボキサミド誘導体
CA2684879A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering rna (sirna)
CN101820764B (zh) 2007-08-27 2014-06-04 海利空医疗公司 治疗用异噁唑化合物
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
JP5529746B2 (ja) 2007-11-21 2014-06-25 デコード ジェネティクス イーエイチエフ 炎症性疾患、心臓血管疾患及び中枢神経系障害を治療するための置換されたベンゾアゾールpde4阻害剤
KR20100098653A (ko) * 2007-11-21 2010-09-08 디코드 제네틱스 이에이치에프 염증의 치료를 위한 바이아릴 pde4 억제제
US20100029689A1 (en) 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010056195A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
CN105143207B (zh) 2013-03-14 2018-04-24 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物

Similar Documents

Publication Publication Date Title
JP2016512259A5 (enExample)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JP2014528446A5 (enExample)
RU2019118623A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2007523182A5 (enExample)
RU2372347C2 (ru) Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2017500364A5 (enExample)
DK2491038T3 (da) Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
JP2019504854A5 (enExample)
RU2012146246A (ru) Антибактериальные производные изохинолин-3-илмочевины
JP2018524331A5 (enExample)
JP2013508403A5 (enExample)
JP2013518046A5 (enExample)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2018535999A5 (enExample)
JP2016519096A5 (enExample)
JP2016514718A5 (enExample)
JP2014531465A5 (enExample)
JP2015514072A5 (enExample)
JP2017502049A5 (enExample)
JP2014518214A5 (enExample)
RU2012133475A (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2015528022A5 (enExample)
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
SI2763982T1 (en) Substituted benzylindazoles for use as inhibitors of Bub kinase in the treatment of hyperproliferative diseases